Cue Biopharma (CUE) Expected to Announce Earnings on Tuesday

Key Points

• Cue Biopharma is expected to report Q2 2026 results before Tuesday’s market open. Analysts project a loss of $1.69 per share and revenue of approximately $3.00 million; the earnings call is scheduled for August 19 at 4:00 p.m. ET.
• The company’s previous quarter exceeded expectations, reporting a loss of $1.08 per share versus the anticipated $3.30 loss and revenue of $5.69 million versus estimates of $2.50 million.
• Shares opened at $26.10 and have declined 3.8%. Analyst sentiment remains negative overall, with MarketBeat reporting an average “Sell” rating, while institutional investors own 35.04% of the stock.

Cue Biopharma (NASDAQ:CUE - Get Free Report) is expected to be announcing its Q2 2026 results before the market opens on Tuesday, August 18th. Analysts expect Cue Biopharma to announce earnings of ($1.69) per share and revenue of $3.00 million for the quarter. Individuals can check the company's upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 19, 2026 at 4:00 PM ET.

Cue Biopharma (NASDAQ:CUE - Get Free Report) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($1.08) earnings per share for the quarter, topping the consensus estimate of ($3.30) by $2.22. The company had revenue of $5.69 million for the quarter, compared to analysts' expectations of $2.50 million. Cue Biopharma had a negative return on equity of 98.30% and a negative net margin of 59.65%.

Cue Biopharma Trading Down 3.8%

Shares of Cue Biopharma stock opened at $26.10 on Tuesday. The firm has a market capitalization of $109.62 million, a P/E ratio of -4.67 and a beta of 2.47. The business has a fifty day simple moving average of $29.31 and a two-hundred day simple moving average of $154.54. Cue Biopharma has a 12 month low of $4.97 and a 12 month high of $45.50.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on CUE shares. Weiss Ratings raised shares of Cue Biopharma from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, May 18th. Wall Street Zen raised shares of Cue Biopharma from a "hold" rating to a "buy" rating in a research note on Saturday, June 6th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of "Sell".

Institutional Investors Weigh In On Cue Biopharma

A number of large investors have recently made changes to their positions in CUE. Northwestern Mutual Wealth Management Co. raised its holdings in Cue Biopharma by 730.0% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company's stock worth $57,000 after purchasing an additional 73,000 shares during the period. Squarepoint Ops LLC purchased a new stake in Cue Biopharma in the third quarter worth about $62,000. Stifel Financial Corp increased its position in Cue Biopharma by 25.4% in the fourth quarter. Stifel Financial Corp now owns 246,556 shares of the company's stock worth $75,000 after buying an additional 50,000 shares in the last quarter. Finally, Boothbay Fund Management LLC raised its stake in shares of Cue Biopharma by 15.3% in the fourth quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company's stock worth $215,000 after buying an additional 93,333 shares during the period. 35.04% of the stock is currently owned by institutional investors.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company's proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source